← Arbutus Biopharma Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.5m |
$10.7m
+617.64%
|
$5.9m
-44.44%
|
$6.0m
+1.11%
|
$6.9m
+15.02%
|
$11.0m
+58.92%
|
$39.0m
+255.11%
|
$18.1m
-53.51%
|
$6.2m
-65.98%
|
$14.1m
+128.21%
|
$191.4m
+1259.40%
|
|
| Research and Development Expense | $61.3m | $62.7m | $57.9m | $57.6m | $47.5m | $65.5m | $84.4m | $73.7m | $54.0m | $25.2m | $20.4m | |
| General and Administrative Expense | $39.4m | $16.1m | $16.0m | $17.7m | $14.7m | $17.1m | $17.8m | $22.5m | $22.1m | $15.9m | $15.9m | |
| Operating Lease, Expense | — | — | — | $1.2m | $700k | $700k | $700k | — | — | — | — | |
| Restructuring Costs | — | — | $396k | — | — | — | — | — | — | — | — | |
| Operating Expenses | $493.1m | $121.6m | $95.7m | $149.9m | $64.7m | $84.5m | $104.5m | $96.2m | $82.5m | $52.2m | $36.4m | |
| Operating Income (Loss) | ($491.6m) |
($110.9m)
+77.44%
|
($89.8m)
+19.07%
|
($143.9m)
-60.28%
|
($57.8m)
+59.83%
|
($73.5m)
-27.19%
|
($65.5m)
+10.97%
|
($78.1m)
-19.32%
|
($76.3m)
+2.28%
|
($38.2m)
+50.00%
|
$155.1m
+506.43%
|
|
| Interest Expense | — | $261k | $226k | $2.1m | $4.0m | $2.9m | $1.7m | $459k | — | — | $86k | |
| Debt Securities, Realized Gain (Loss) | — | — | — | — | — | — | $100k | $100k | $100k | $100k | — | |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | $530k | ($22k) | $0 | — | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | $1.1m | $2.3m | ($1.0m) | $41k | ($124k) | $5k | ($22k) | $25k | ($49k) | $14k | — | |
| Gain (Loss) on Investments | — | — | $24.9m | — | — | — | — | — | — | — | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $137k | $97k | $86k | |
| Income (Loss) from Equity Method Investments | — | — | ($5.6m) | ($22.5m) | ($2.5m) | $0 | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | ($27.1m) | ($1.8m) | ($7.7m) | ($28.7m) | ($14.8m) | ($1.6m) | $12.0m | $160.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | ($166.4m) | ($63.7m) | — | — | — | — | — | $160.7m | |
| Income Tax Expense (Benefit) | ($105.0m) | ($24.3m) | ($4.3m) | ($12.7m) | $0 | $0 | $4.4m | $0 | $0 | $0 | $0 | |
| Net Income (Loss) Attributable to Parent | ($384.2m) |
($84.4m)
+78.03%
|
($57.1m)
+32.40%
|
($153.7m)
-169.41%
|
($63.7m)
+58.53%
|
($76.2m)
-19.61%
|
($69.5m)
+8.91%
|
($72.8m)
-4.89%
|
($69.9m)
+4.02%
|
($33.5m)
+52.09%
|
$160.7m
+579.75%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | — | ($85.3m) |
($67.2m)
+21.30%
|
($164.9m)
-145.52%
|
($75.9m)
+53.98%
|
($88.4m)
-16.50%
|
($69.5m)
+21.42%
|
— | — | — | $160.7m | |
| Preferred Stock Dividends and Other Adjustments | — | $911k | $10.1m | $11.1m | $12.1m | $12.1m | $0 | — | — | — | — | |
| Earnings Per Share, Basic | ($7.24) | ($1.56) | ($1.21) | — | — | ($0.83) | ($0.46) | ($0.44) | ($0.38) | ($0.17) | $0.84 | |
| Earnings Per Share, Diluted | ($7.24) | ($1.56) | ($1.21) | — | — | ($0.83) | ($0.46) | ($0.44) | ($0.38) | ($0.17) | $0.83 | |
| Weighted Average Number of Shares Outstanding, Basic | 53.1m | 54.7m | 55.3m | — | — | 106.2m | 150.9m | 166.0m | 185.6m | 191.6m | 192.4m | |
| Weighted Average Number of Shares Outstanding, Diluted | 53.1m | 54.7m | 55.3m | — | — | 106.2m | 150.9m | 166.0m | 185.6m | 191.6m | 192.7m | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | $138.2m | $0 | $0 | $22.5m | $0 | — | — | — | — | — | — | |
| Income (Loss) Attributable to Parent, before Tax | — | — | — | — | — | — | ($65.0m) | ($72.8m) | ($69.9m) | ($33.5m) | — |